Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 1Solid Tumor, Adult 1Neoplasms 1Glioblastoma 1

Interventions

Cetuximab 5pembrolizumab 3Injections 3Bevacizumab 2taxane 1ribociclib 1pegylated granulocyte colony-stimulating factor 1olaparib 1fludarabine phosphate 1fludarabine 1encorafenib 1dapagliflozin 1cemiplimab 1binimetinib 1anlotinib 1amivantamab 1adagrasib 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Irinotecan 1Immunotherapy, Adoptive 1IFL protocol 1Folfox protocol 1Fluorouracil 1Filgrastim 1Docetaxel 1Cyclophosphamide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Solid Tumors × amivantamab × Clear all
NCT06816992 2026-04-24

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

ORIC Pharmaceuticals

Phase 1 Recruiting
76 enrolled
Other solid neoplasmThoracic

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡